Urinary Stone Disease - 0 views
GSK submits sNDA for Promacta to FDA for severe aplastic anaemia treatment - 0 views
Evotec, Debiopharm to research and develop new cancer treatments - 1 views
FDA approves Xolair for treatment of chronic hives - 1 views
Medico legal companies - 0 views
-
The right to healthcare requires ensuring that appropriate physical health services are available without discrimination and are accessible, acceptable and of good quality. Medico legal case (MLC) is a case where besides the medical treatment; police investigations are essential to fix the responsibility regarding the present condition of the patient.
-
The right to healthcare requires ensuring that appropriate physical health services are available without discrimination and are accessible, acceptable and of good quality. Medico legal case (MLC) is a case where besides the medical treatment; police investigations are essential to fix the responsibility regarding the present condition of the patient.
Boehringer's Pradaxa gets FDA approval for DVT, PE treatment - 1 views
GlaxoSmithKline's Tanzeum gets FDA approval for type 2 diabetes treatment - 1 views
GlaxoSmithKline's once-weekly diabetes drug Eperzan gets marketing approval in Europe - 1 views
-
PBR Staff Writer Published 27 March 2014 The European Commission (EC) has granted marketing authorization for GlaxoSmithKline's (GSK's) once-weekly diabetes treatment, Eperzan (albiglutide). The drug is indicated for the treatment of type 2 diabetes mellitus in adults, to improve glucose control as monotherapy, when diet and exercise alone do not provide adequate glycaemic control in patients for whom the use of metformin is considered inappropriate due to contraindications or intolerance.
Otsuka- Lundbeck's schizophrenia drug Abilify Maintena gets Health Canada clearance - 0 views
Bristol-Myers Squibb gets FDA breakthrough designation for daclatasvir-based regimen - 0 views
-
PBR Staff Writer Published 25 February 2014 Bristol-Myers Squibb (BMS) has received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) for its investigational DCV Dual Regimen (daclatasvir and asunaprevir) for use as a combination therapy in the treatment of genotype 1b chronic hepatitis C infection (HCV).